Infectious diseases
AutoGenomics
The company's mission is to empower clinical laboratories with an automated multiplexing MDx solution to perform molecular testing that will significantly enhance work flow, cost efficiency and turn-around time resulting in enhanced patient care.
Sexually Transmitted Diseases

Concurrent diagnoses in genital tract infections are frequent. Broad testing on the initial visit, instead of treating one entity at a time, could improve outcomes and save money.
The INFINITI® STD-6 Panel is designed to identify the presence of six pathogenes that are associated with sexually transmitted diseases in humans: Chlamydia trachomatis, Neisseria gonorrhea, Ureaplasma urealyticum, Mycoplasma genitalium, Mycoplasma hominis and Trichomonas vaginalis. The tests contains an amplification control to monitor assay performance.
Other INFINITI® infectious diseases tests are HPV Genotyping, HPV QUAD, RVP (Respiratory Viral Panel), CT-NG QUAD (Chlamydia trachomatis / Neisseria gonorrhea), MDR-TB (multi drug resistance tuberculosis) and NTM (nontuberculous mycobacteria).
HPV-HR QUAD (Human Papillomavirus) |
[PDF 800KB] |
RVP Plus (Respiratory Viral Panel + Swine H1N1) |
[PDF 800KB] |
FLU A - Swine H1N1 |
[PDF 800KB] |
Sexually Transmitted Diseases (STD) Product Family |
|
|
[PDF 800KB] |
|
[PDF 800KB] |
|
[PDF 800KB] |
|
[PDF 800KB] |
|
[PDF 800KB] |
|
[PDF 800KB] |
MDR-TB (Multi Drug Resistance) |
[PDF 800KB] |
NTM (Nontuberculous Mycobacteria) |
[PDF 800KB] |
Contact
Baselstr. 55
CH-4124 Schönenbuch
Switzerland
Fon: +41 61 487 12 12
Fax: +41 61 487 12 34
info@buhlmannlabs.ch
| Your local distributor Order About us Job opportunities |
Search
News
The recently launched EntroGen BRAF (V600E/K/D) test, that can be run on your real-time PCR instrument, is now CE-IVD marked
The EntroGen BRAF (V600E/K/D) test is a very useful tool for the detection of important mutations found in melanoma, because it detects, beside the V600E more
INFINITI KRAS-BRAF study from the Basel Institut of Pathology published in the Diagnostic Molecular Pathology journal.
New publication about the INFINITI KRAS assay in the Journal Diagn Mol Path 21/1 2012 14-23, Bihl et al. In this study from the Institute of Pathology at more
Recent publications on BÜHLMANN calprotectin assays
Three very interesting new papers have been published recently. Manz et al. describes the quality and usefulness of the BÜHLMANN calprotectin ELISA in an more
NEW OWN CALPROTECTIN REIMBURSEMENT POSITION IN SWITZERLAND
BÜHLMANN is very proud to announce that the calprotectin determination in stool starting from January 1st 2012, has an official new position in the reimb more
BÜHLMANN Core | BÜHLMANN Molecular | BÜHLMANN Medical | Customer Relations | About Us |
Contact |
